Raising the standards of patient‐centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS‐RIGHT project

• Published in: Cancer medicine (Malden, MA) MA), 2023-03, Vol.12 (6), p.7529-7539
• Main Authors: Efficace, Fabio, Koinig, Karin, Cottone, Francesco, Bowen, David, Mittelman, Moshe, Sommer, Kathrin, Langemeijer, Saskia, Culligan, Dominic, Filanovsky, Kalman, Storck, Michael, Smith, Alexandra, van Marrewijk, Corine, Dugas, Martin, Stojkov, Igor, Siebert, Uwe, de Witte, Theo, Stauder, Reinhard
• Format: Article
• Language: English
• Subjects: Aged; Anemia; Clinical decision making; Comorbidity; Cronbach's alpha; Decision making; Factor analysis; Hemoglobin; Humans; myelodysplasia; Myelodysplastic syndrome; Myelodysplastic syndromes; Myelodysplastic Syndromes - drug therapy; Myelodysplastic Syndromes - therapy; Patient Outcome Assessment; Patients; patient‐reported outcomes; Prospective Studies; Quality of Life; questionnaire; Questionnaires; Sociodemographics; symptom burden; Validity
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.5487

Background Clinical decision‐making for patients with myelodysplastic syndromes (MDS) is challenging, and both disease and treatment effects heavily impact health‐related quality of life (HRQoL) of these patients. Therefore, disease‐specific HRQoL measures can be critical to harness the patient voice in MDS research. Methods We report a prospective international validation study of the Quality of Life in Myelodysplasia Scale (QUALMS) with a main focus on providing information on the psychometric characteristics of its three subscales: physical burden (QUALMS‐P), emotional burden (QUALMS‐E), and benefit finding (QUALMS‐BF). The analysis is based on patients enrolled from three European countries and Israel, participating to the MDS‐RIGHT Project. The scale structure and psychometric properties of the QUALMS were assessed. Results Overall, 270 patients with a median age of 74 years were analyzed and the majority of them (60.3%) had a low MDS‐Comorbidity Index score. Results of the confirmatory factor analysis supported the underlying scale structure of the QUALMS, which, in addition to a total score, includes three subscales: QUALMS‐P, QUALMS‐E, and the QUALMS‐BF. The QUALMS‐P exhibited the highest Cronbach's alpha coefficients. Discriminant validity analysis indicated good results with the QUALMS‐P and QUALMS‐E distinguishing between patients with different performance status, comorbidity, anemia, and transfusion dependency status. No floor and ceiling effects were observed. Responsiveness to change analysis supported the validity of the measure. Patients with a hemoglobin (Hb) level of